Work

Rethinking Lipoprotein(a) Trial Design: The Case for Phenotype-Guided Enrichment

Year: 2026
Type: article
Abstract: Lipoprotein(a) [Lp(a)] is an unusual cardiovascular risk factor.Its plasma concentration is largely genetically determined, is essentially fixed from early childhood, and is barely influenced by lifestyle or the more commonly used lipid-lowering drugs.Epidemiological, genetic and Mendelian randomisation studies converge on a causal role in both atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis [1-3].Around one in five people of European ancestry carry levels above 105 nmol/L, which per se are considered a cardiovascular risk-enhancing factor, and guidelines on both sides of the Atlantic now recommend measuring Lp(a) at least once in every adult [1,4,5].Yet, until now, there has been no targeted treatment to offer those found to be at risk.
Language: English
Field: Medicine
Open Access status: bronze
OpenAlex ID: W7236454653
FWCI:
Cites: 9
Cited by:
Related to: 10